Next, to determine if there was a link between cfDNA levels and endothelial dysfunction and inflammation in CKD [17–20], we measured concentrations of cfDNA and inflammatory cytokines in 70 patients treated with either placebo or the peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone for 8 weeks [15]. This evidence concerns the gene PPARG and endothelial dysfunction.